Avacta Group reported a marginal rise in group revenue to £24.42m, with diagnostics division sales increasing by 14.7%. However, therapeutics revenue fell to £0.11m due to the absence of milestones from AffyXell. Avacta continues to expand its clinical and research activities, advancing its lead preCISION programme AVA6000 into phase 1b trials across multiple cancers. The company also progressed its second candidate, AVA6103, into IND-enabling studies with plans for a phase one trial in early 2026. A strategic collaboration with Tempus was formed to integrate AI-driven trial design and patient identification, showcasing Avacta’s commitment to innovation and growth.
Read more from cbinsights.com
